secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001193125-26-085474
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Nuvation Bio Reports Q4 2025 Revenue of $15.7M, 216 New IBTROZI Patient Starts
------------------------------------------------------------------------------

- IBTROZI (taletrectinib) launched in June 2025; 432 new patient starts by end of Q4 2025, with 216 in Q4 alone.
- Entered exclusive licensing/collaboration with Eisai on Jan 11, 2026 for taletrectinib in Europe and other regions.
- Cash, equivalents, and marketable securities of $529.2M as of Dec 31, 2025.
- Net product revenue from IBTROZI: $15.7M in Q4 2025, $24.7M for full year 2025.
- Positive Phase 2 safusidenib results published; ORR 44%, 88% progression-free at 24 months in grade 2 IDH1-mutant glioma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312526085474/0001193125-26-085474-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312526085474/d15383d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-085474

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer